ABSTRACT
Objective:To investigate the clinical effect of mindfulness-based therapy combined with risperidone treatment on emotional disorder in schizophrenic patients during the recovery period.Methods:A total of 106 schizophrenic patients during the recovery period who received treatment from March 2017 to February 2019 in The Second Hospital of Jinhua,China were included in this study.They were randomly assigned to undergo mindfulness-based therapy combined with risperidone treatment alone (study group, n = 53) or risperidone treatment (control group, n = 53).The Positive and Negative Syndrome Scale (PANSS) score and Scale of Social Function in Psychosis Inpatients (SSPI) score were compared between study and control groups before and after treatment. Results:Before treatment,there were no significant differences in PANSS total score,negative scale score,positive scale score,general psychopathology scale score between study and control groups (all P > 0.05).After treatment,negative scale score,positive scale score,general psychopathology scale score and PANSS total score in the study group were (11.54 ± 1.63) points,(11.56 ± 1.61) points,(21.71 ± 1.85) points,(44.66 ± 3.01) points respectively,and they were (15.31 ± 1.91) points,(15.29 ± 1.89) points,(23.51 ± 2.11) points,(52.06 ± 3.32) points,respectively in the control group.After treatment,negative scale score,positive scale score,general psychopathology scale score and PANSS total score in each group were significantly lower than those before treatment (study group: t = 10.352,10.337,8.419,15.630; control group: t = 2.607,2.601,4.534,7.131,all P < 0.05).After treatment,negative scale score,positive scale score,general psychopathology scale score and PANSS total score in the study group were significantly lower than those in the control group ( t = 10.930,10.937,4.670,12.022,all P < 0.05).Before treatment,there were no significant differences in scores of activities of daily living,social skills and initiative and communication between the two groups (all P > 0.05). After treatment,scores of social skills,activities of daily living and initiative and communication in the study group were (12.88 ± 1.62) points,(10.58 ± 1.54) points,(13.14 ± 1.97) points respectively,and they were (11.92 ± 1.56) points,(9.01 ± 1.43) points,and (11.46 ± 1.69) points respectively in the control group.After treatment,scores of social skills,activities of daily living and initiative and communication in each group were significantly higher than those before treatment (study group: t = 6.783,5.475,4.430; control group: t = 3.956,2.263,2.009,all P < 0.05).After treatment,scores of social skills,activities of daily living and initiative and communication in the study group were significantly higher than those in the control group ( t = 3.108,5.439,4.712,all P < 0.05). Conclusion:Mindfulness-based therapy combined with risperidone treatment for emotional disorder in schizophrenic patients during the recovery period can effectively improve the emotional disorder,reduce the schizophrenia symptoms,and improve the social function of patients.
ABSTRACT
Objective To evaluate the effect of Tandospirone citrate in the treatment of Alzheimer's disease with depression and anxiety disorder. Methods A total of 122 patients with Alzheimer's disease with depression and anxiety were enrolled at the Second Hospital of Jinhua City from January 2015 to December 2016.They were randomly divided into the Lorazepam group(n=61) and the Tandospirone citrate(ADHA)(n= 61).The behavioral pathology in Alzheimer's disease (BEHAVE-AD),self-care ability scale(ADL),Hamilton anxiety scale(HAMA)and Hamilton depression scale(HAMD)were evaluated in the two groups after three weeks of treatment.The BEHAVE-AD,ADL,HAMA,and HAMD scores and the incidence of adverse reactions were compared between the two groups before and after treatment. Results Baseline scores of BEHAVE-AD, ADL,HAMA and HAMD were not significantly different between the two groups(all P> 0.05). However,post-treatment scores of BEHAVE-AD,ADL,HAMA and HAMD were significantly lower than pre-treatment scores(all P< 0.05),and were more significantly decreased in the Tandospirone citrate group(all P<0.05).Furthermore,the incidence of adverse reactions was significantly lower in the Tandospirone citrate group than that in the Lorazepam group(6.5% vs.19.7%,P< 0.05). Conclusions Compared with Lorazepam,Tandospirone citrate is clinically more effective for Alzheimer's disease complicated with anxiety and depressive disorder.